FGFR3 alteration
Showing 1 - 25 of 4,138
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma Trial in Duarte, Iowa City, New York
Recruiting
- Advanced Solid Tumor
- +13 more
- [225Ac]-FPI-1966
- +2 more
-
Duarte, California
- +3 more
Oct 25, 2022
Breast Tumor, Radiotherapy, Breath Holding Trial in Ghent (Mental Exercises and Temporal Alteration)
Not yet recruiting
- Breast Neoplasm
- +3 more
- Mental Exercises and Temporal Alteration
-
Ghent, BelgiumUniversity Hospital - Radiotherapy Department
Oct 20, 2023
Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)
Recruiting
- Advanced or Recurrent Solid Tumors
- FGFR Gene Alterations
-
Aoba-ku, Sendai, Miyagi, Japan
- +4 more
May 9, 2022
Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)
Recruiting
- Urinary Bladder Neoplasms
- +2 more
-
New York, New York
- +2 more
Jan 31, 2023
Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))
Terminated
- Solid Tumours
- Debio1347 (CH5183284)
-
Boston, Massachusetts
- +7 more
Sep 8, 2020
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)
Active, not recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Infigratinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2022
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life
Active, not recruiting
- FGFR1 Gene Amplification
- +18 more
- Pemigatinib
- Quality-of-Life Assessment
-
Scottsdale, Arizona
- +5 more
Oct 18, 2022
Bladder Cancer Trial in Vandœuvre-lès-Nancy (Urine collection (150ml), Blood sample (20 ml))
Recruiting
- Bladder Cancer
- Urine collection (150ml)
- Blood sample (20 ml)
-
Vandœuvre-lès-Nancy, FranceInstitut de Cancérologie de Lorraine
Mar 23, 2022
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)
Not yet recruiting
- Locally Advanced Urothelial Carcinoma
- +3 more
- (no location specified)
Sep 15, 2022
Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)
Recruiting
- Gastrointestinal Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Dec 7, 2022
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in
Recruiting
- Locally Advanced Gastrointestinal Stromal Tumor
- +7 more
- Biopsy
- +4 more
-
Duarte, California
- +17 more
Feb 2, 2023
NSCLC (NSCLC) Trial in Worldwide (Pemigatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
Los Angeles, California
- +41 more
Jun 27, 2022
Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy Trial in Arlington Heights (Panzyga IVIG,
Not yet recruiting
- Small Fiber Neuropathy
- +3 more
- Panzyga IVIG
- Placebo
-
Arlington Heights, IllinoisNorthwest Community Healthcare
Aug 22, 2022
Infection Trial in Canada (Fecal Microbiota Transplantation (FMT))
Suspended
- Infection
- Fecal Microbiota Transplantation (FMT)
-
Brampton, Ontario, Canada
- +12 more
Nov 1, 2022
Low-grade Glioma Trial (DAY101, Chemotherapeutic Agent)
Not yet recruiting
- Low-grade Glioma
- DAY101
- Chemotherapeutic Agent
- (no location specified)
Oct 3, 2022
Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)
Recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 15, 2022
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma Trial in Canada, Germany, United States (Infigratinib)
Not yet recruiting
- Advanced Solid Tumor
- +2 more
-
Palo Alto, California
- +9 more
Aug 2, 2022
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody
Recruiting
- Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
- AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Sep 12, 2023
Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Recruiting
- Bladder Cancer
- +12 more
-
Raleigh, North CarolinaxCures Virtual Site
Sep 20, 2021
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)
Recruiting
- Breast Cancer
- +3 more
- Infigratinib
- +3 more
-
Stanford, CaliforniaStanford University
Feb 16, 2022